Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international b.v. - virus ħaj tal-bronkite infettuża tat-tjur, razza d388 - live viral vaccines, domestic fowl - chicken - għal immunizzazzjoni attiva tat-tiġieġ sabiex jitnaqqsu s-sinjali respiratorji ta 'bronkite infettiva tat-tjur ikkawżata minn varjanti bħal qx ta' virus ta 'bronkite infettiva.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - libertek huwa indikat għall-manutenzjoni trattament severi kronika eliminat pulmonari marda (copd) (fev1 bronchodilator wara inqas minn 50% mbassra) assoċjati ma ' bronchitis kroniċi fil-pazjenti adulti bi storja ta ' spiss exacerbations bħala żieda trattament bronchodilator.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - fentanyl - pain; cancer - analġeżiċi - pecfent huwa indikat għall-amministrazzjoni tal-uġigħ rivoluzzjonarji fl-adulti li huma diġà li tirċievi manteniment terapija opioid għal kanċer kronika uġigħ. l-uġigħ fil-qosor huwa aggravament tranżitorju ta 'uġigħ li jseħħ fuq sfond ta' uġigħ persistenti ikkontrollat ​​mod ieħor. pazjenti li kienu qed jirċievu l-manutenzjoni terapija b'opioid huma dawk li qed jieħdu ta 'lanqas 60 mg ta' morfina orali kuljum, mill-inqas 25 mikrogramma ta 'fentanyl transdermali kull siegħa, mill-inqas 30 mg ta' oxycodone kuljum, mill-inqas 8 mg ta 'hydromorphone orali kuljum jew equi-analġeżiku tad-doża ta' opioid ieħor għal ġimgħa jew aktar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sklerosi multipla - immunosuppressanti selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - aġenti għad-dermatite, esklużi kortikosterojdi - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

endoceutics s.a. - prasterone - postmenopause - oħrajn tal-ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema - intrarosa hija indikata għat-trattament ta 'atrofija vulvari u vaġinali fin-nisa wara l-menopawża li għandhom sintomi moderati sa severi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios hipra s.a. - virus ħaj inattivat tal-respiratorja bovina-virus sinktjali (brsv), razza lym-56 - immunoloġiċi għall-bovini, baqar, vaċċini virali Ħajjin, respiratorja bovina-virus sinktjali (brsv) - bhejjem - tilqim attiv ta ' baqar biex jitnaqqsu l-virus jixħtu u respiratorji is-sinjali kliniċi ikkawżati mill-respiratorja bovina-infezzjoni tal-virus sinktjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - siponimod-aċidu fumariku - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosuppressanti selettivi - mayzent huwa indikat għall-kura ta ' pazjenti adulti bi sklerożi multipla progressiva sekondarja (spms), bil-marda attiva muri mill-irkadar jew l-immaġini tal-karatteristiċi ta'l-attività infjammatorja.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - l-osteoporożi - drogi għat-trattament ta 'mard tal-għadam - evenity huwa indikat fit-trattament ta 'l-osteoporożi fin-nisa wara l-menopawsa f'riskju għoli ta' ksur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - fingolimod hydrochloride - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti, selettiv immunosuppressanti - indikat bħala terapija li timmodifika l-marda waħda fl attiva ħafna sklerożi multipla li tirkadi u tbatti l-isklerożi multipla għal dawn il-gruppi ta 'pazjenti adulti u pazjenti pedjatriċi ta'bejn l-10 snin u akbar:pazjenti b'ħafna marda attiva minkejja sħiħa u adegwata-kors tal-kura b'mill-inqas waħda li timmodifika l-marda therapyorpatients mal li qed tevolvi malajr severa sklerożi multipla li tirkadi u tbatti l-isklerożi multipla definita minn 2 jew iktar diżabilità attakki reċidivi fis-sena, u b'1 jew aktar gadolinium-tisħiħ tal-leżjonijiet fuq il-moħħ ta' l-mri jew żieda sinifikanti fil-t2 tal-leżjonijiet tat-tagħbija kif meta mqabbel ma 'qabel riċenti ta' l-mri.